NCT04967014View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

June 1, 2021

Study Completion Date

June 18, 2021

Conditions
Healthy Adult Volunteer
Interventions
DRUG

HIP2101

Test drug

DRUG

RLD2101

Reference drug

Trial Locations (1)

Unknown

Chungbuk University Hospital, Cheongju-si

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04967014 - Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter